Search

Your search keyword '"Razmjou, Amir A."' showing total 583 results
Start Over Author "Razmjou, Amir A."
583 results on '"Razmjou, Amir A."'

1. Disease response in rheumatoid arthritis across four biologic therapies associates with improvement in paraoxonase-1 activity and oxylipins.

Author

Razmjou, Amir, Kremer, Joel, Pappas, Dimitrios, Curtis, Jeffrey, Wang, Jennifer, Shahbazian, Ani, Elashoff, David, Guo, Rong, Meriwether, David, Sulaiman, Dawoud, OConnor, Ellen, Reddy, Srinivasa, and Charles-Schoeman, Christina

Subjects
arthritis, rheumatoid, biological therapy, cardiovascular diseases, Humans, Aryldialkylphosphatase, Arthritis, Rheumatoid, Oxylipins, Female, Male, Middle Aged, Antirheumatic Agents, Biomarkers, Aged, Treatment Outcome, Adult, Antibodies, Monoclonal, Humanized, Biological Therapy, Rituximab, Severity of Illness Index, Abatacept, Tumor Necrosis Factor Inhibitors
Abstract

OBJECTIVE: Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme, that has been implicated as a biomarker of cardiovascular risk in patients with rheumatoid arthritis (RA). We aimed to investigate how different biologic therapies affect levels of PON1 and oxylipins. METHODS: 1213 adult patients with RA in the Comparative Effectiveness Registry to study Therapies for Arthritis and Inflammatory CoNditions cohort study with moderate-to-high disease activity (Clinical Disease Activity Index (CDAI) >10) who initiated a new biologic (tocilizumab (TCZ), n=296; abatacept, n=374; tumour necrosis factor inhibitors, n=427; rituximab, n=116) were followed prospectively with serum specimens analysed for PON1 activity by arylesterase (ARYL), lactonase (LAC) and PON assays at baseline and after 6 months of biologic therapy. A targeted panel of oxylipins was evaluated by liquid chromatography-mass spectrometry/mass spectrometry in a subset of patients with the lowest and highest 6-month Disease Activity Score 28 (DAS28)-C reactive protein (CRP) responses in each treatment group. RESULTS: PON1 activity generally increased in the entire cohort after 6 months of new biologic therapy, showing the greatest, most consistent increases in the TCZ group. Increases in all three PON1 domains associated with significant decreases in disease activity in DAS28-CRP/CDAI (p

Published
2024

23. Ultrasound and multi-biomarker disease activity score for assessing and predicting clinical response to tofacitinib treatment in patients with rheumatoid arthritis

Author

Razmjou, Amir A, Brook, Jenny, Elashoff, David, Kaeley, Gurjit, Choi, Soo, Kermani, Tanaz, and Ranganath, Veena K

Subjects
Autoimmune Disease, Clinical Research, Arthritis, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Inflammatory and immune system, Rheumatoid arthritis, Ultrasound, Outcome measures, Multi-biomarker disease activity score
Abstract

BackgroundMusculoskeletal ultrasound (MSUS) and the multi-biomarker disease activity (MBDA) score are outcome measures that may aid in the management of rheumatoid arthritis (RA) patients. This study evaluated tofacitinib response by MSUS/MBDA scores and assessed whether baseline MSUS/MBDA scores or their early changes predict later clinical response.MethodsTwenty-five RA patients treated with tofacitinib were assessed at baseline, 2, 6 and 12-weeks. Power doppler (PDUS) and gray scale (GSUS) ultrasound scores, MBDA score, clinical disease activity index (CDAI), and disease activity score (DAS28) were obtained. Pearson correlations and multiple linear regression models were used to evaluate associations and identify predictors of response to therapy.ResultsMSUS, MBDA scores, CDAI, and DAS28 improved significantly over 12 weeks (p

Published
2020

32. Ion Selective Membranes

Author

Ejeian, Fatemeh, primary, Sadeghi, Samira, additional, Zargar, Masoumeh, additional, Arshadi, Faezeh, additional, Noorisafa, Fatemeh, additional, and Razmjou, Amir, additional

Published
2023
Full Text
View/download PDF

33. A Case of Granulomatosis with Polyangiitis: Consequences of Delayed Diagnosis in a Life-threatening Malady

Author

Razmjou, Amir A, Seo, Young-Ji, Ayoub, Michael F, Zuckerman, Jonathan, and Patel, Satya

Subjects
Clinical Research, Prevention, Lung, Kidney Disease, Evaluation of treatments and therapeutic interventions, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, 6.1 Pharmaceuticals, Inflammatory and immune system, Renal and urogenital, Good Health and Well Being, anca vasculitis, granulomatosis with polyangiitis, wegener granulomatosis, Medical and Health Sciences
Abstract

Granulomatosis with polyangiitis (GPA) is one of three described anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). Early diagnosis and treatment of GPA is paramount, as it may help prevent irreversible end-organ damage, especially renal and pulmonary failure. A 72-year-old male with a past medical history of lung adenocarcinoma in remission, chronic sinusitis status-post multiple sinus surgeries, and coronary artery disease presented with shortness of breath, dark urine, and asymmetric polyarthralgias. He had an acute kidney injury, leukocytosis, with urinalysis demonstrating pyuria and hematuria, without casts. Chest imaging showed cavitary nodular opacities in addition to interval increase of existing nodules compared to the most recent scan one month prior. His acute kidney injury progressed to renal failure requiring hemodialysis, and he developed an inflammatory polyarthritis. GPA was suspected clinically so he was started on high-dose intravenous corticosteroids, and subsequently plasmapheresis and rituximab. Serology returned with highly positive proteinase-3 antibodies, and cytoplasmic ANCA positivity on immunofluorescence. Renal biopsy demonstrated severely active pauci-immune glomerulonephritis. Several months after discharge, the patient passed away from gram positive bacteremia. This patient's recurrent sinusitis, pulmonary nodules, and subsequent renal failure were highly suggestive of GPA. A biopsy is recommended to confirm the diagnosis of GPA, but treatment should not be delayed if there is a high index of suspicion for the disease. Induction therapy with corticosteroids combined with rituximab or cyclophosphamide has significantly decreased the mortality of patients with GPA. Patients with GPA often have preceding history of nasopharyngeal and upper airway disease, and can present with fluctuating pulmonary infiltrates. Early recognition and treatment of patients with GPA can prevent life-threatening complications and reduce mortality.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results